Collaboration with Oncology and Evolution of Targeted Therapies

Ask the Experts: A Lifelong Learning Series - October 2021
Collaboration with Oncology and Evolution of Targeted Therapies

John H. Shin, MD
C. Rory Goodwin, MD, PhD
Joshua C. Patt, MD, MPH

Disclosures:

Goodwin, C. Rory: Consulting: Medtronic (B); Grants: Federal Food And Drug Administration (G, Paid directly to institution/employer), NIH/NINDS (F, Paid directly to institution/employer), Robert Wood Johnson Foundation (F, Paid directly to institution/employer).

Patt, Joshua C.: Board of Directors: AOA (Nonfinancial, Council of Orthopaedic Residency Directors Chair, Executive Committee Member).

Shin, John H.: Consulting: Carbofix (None), DePuy (B), Medtronic (A), NuVasive (B).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+